Industry fears that US FDA-CMS review could harm device innovation
This article was originally published in Clinica
The US health department's proposal to establish a programme that would allow the FDA and the Centers for Medicare and Medicaid Services (CMS) to jointly review new medical devices under development is well-intended but may have negative consequences on innovation, says medtech industry association AdvaMed.
You may also be interested in...
An independent audit of the new EU Clinical Trials Information System has finally commenced, indicating that plans are on track for the EU Clinical Trial Regulation to be implemented from December 2021.
EU regulators have agreed on supplementary pharmacovigilance requirements applicable to COVID-19 vaccines following approval.
The UK Medicines and Healthcare products Regulatory Agency wants clinical trial sponsors to integrate available regulatory flexibilities into normal practice so that their studies can withstand further potential disruptions from the COVID-19 pandemic.